Department of Pediatrics

Model helps predict which infants may go on to develop NAS

A new Vanderbilt-designed prediction model may make it easier to determine which infants will go on to develop neonatal abstinence syndrome (NAS), a drug withdrawal syndrome in newborns that occurs after exposure to opioids during pregnancy.

New treatment for a rare obesity

Diabetes drugs known as GLP-1 receptor agonists, such as exenatide (Byetta), are a promising and safe treatment for a rare form of obesity.

VUMC begins study of second COVID-19 vaccine

Vanderbilt University Medical Center has begun recruiting up to 250 participants for a Phase 3 clinical trial testing an investigational COVID-19 vaccine candidate developed by the Janssen Pharmaceutical Companies of Johnson & Johnson.

COVID treatment studied by VUMC gains FDA approval

Researchers at Vanderbilt University Medical Center played a key role in the development of remdesivir, the first drug approved by the U.S. Food and Drug Administration for the treatment of COVID-19.

Cancer centers nationwide join to address the impact of COVID-19 pandemic on cancer prevention and treatment

A consortium of 17 cancer centers in the United States, including Vanderbilt-Ingram Cancer Center, have come together to better understand the consequences of the COVID-19 pandemic in delaying cancer detection, care and prevention.

Some children with COVID-19 may experience rare inflammatory syndrome

With cases of COVID-19 increasing among young children and adolescents in Tennessee, pediatric infectious disease experts at Monroe Carell Jr. Children’s Hospital at Vanderbilt have started to see cases of a mysterious illness believed to be connected to COVID-19, known as multi-inflammatory syndrome in children (MIS-C).

1 25 26 27 28 29 56